Clinical analysis of interstitial pneumonia after surgery for lung cancer.
OBJECTIVE
The postoperative development or exacerbation of interstitial pneumonia (IP) in lung cancer patients often affects prognoses. We analyzed the patients who suffered from IP after surgery, to determine treatment and prevention of IP.


METHODS
One hundred and one consecutive patients who underwent resection were enrolled in the study. Clinical background and post-, perioperative course were compared between patients who developed IP and those who did not.


RESULTS
If IP developed or was exacerbated, steroid pulse (SP) therapy, immunosuppressant (IS) therapy or nitric oxide (NO) inhalation therapy was employed. Of 101 patients, 20 had suffered from IP before surgery. In four of these 20 (20%), postoperative exacerbation was observed. SP therapy was given to all patients. To one patient, IS and NO therapy were added. Three of the four patients died. 81 patients did not have IP; three of them (3.7%) developed IP after the operation and were treated with SP therapy. To one patient, IS and NO therapy were added. Two of the three patients died. IP development or exacerbation after surgery was observed in seven of 101 patients, and five of them died. It was significantly more frequent in patients with poorly differentiated squamous cell carcinoma, restrictive change in pulmonary function tests, and a low percentage diffusion capacity for carbon monoxide. Postoperative development or exacerbation was observed in patients who had undergone lobectomy or pneumonectomy.


CONCLUSIONS
Postoperative IP is a serious complication. Further studies are needed to determine definitive therapeutic options. For the patients with the aforementioned risk factors, limited surgery must be considered.
Second Department of Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Taku
T
Okamoto
Masashi
M
Gotoh
Daiki
D
Masuya
Takashi
T
Nakashima
Dage
D
Liu
Kotaro
K
Kameyama
Shinya
S
Ishikawa
Yasumichi
Y
Yamamoto
Cheng-Long
CL
Huang
Hiroyasu
H
Yokomise
D000230:Adenocarcinoma / Q000150:complications / Q000601:surgery*; D000280:Administration, Inhalation; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000601:surgery*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017563:Lung Diseases, Interstitial / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D008175:Lung Neoplasms / Q000150:complications / Q000601:surgery*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage; D011013:Pneumonectomy / Q000009:adverse effects*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D007166:Immunosuppressive Agents; D009569:Nitric Oxide; D003520:Cyclophosphamide; D008775:Methylprednisolone